Seeking Alpha

Novartis' (NVS) LCZ696 drug for patients with ejection fraction heart failure, in which the...

Novartis' (NVS) LCZ696 drug for patients with ejection fraction heart failure, in which the organ's chambers are stiff but can still pump a reasonable amount of blood, performed well in a mid-stage trial. LCZ696 reduced levels of NT-proBNP, a protein that's linked to the condition. Larger studies are now needed to see whether this "biomarker" can lead to improved results in clinical practice.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|